Darwin AG, a European healthcare company specializing in human genetics, has officially changed its name to Novogenia AG following the registration of the amendment to its Articles of Association in the Commercial Register on July 15, 2026. The name change, approved at the Annual General Meeting on June 26, 2026, aligns the corporate identity with its core operating brand, Novogenia GmbH, which has been the primary driver of the group's business and growth.
The company, previously listed under ISIN DE000A3C35W0, will now operate under the name Novogenia AG. According to Dr. Daniel Wallerstorfer, CEO of Novogenia AG, the move unifies the company's market presence and reinforces its ambition to become a leading international provider of personalized healthcare and longevity solutions. “Novogenia has been at the heart of our operational business and our international market presence for many years. By operating under the name Novogenia AG, we are consistently unifying our corporate and brand identities,” Wallerstorfer stated.
Novogenia GmbH has been active in human genetics for years, developing and selling personalized products based on genetic analysis. The Novogenia brand is known for its scientific expertise and technological innovation. The name change simplifies corporate structure and communication, creates a consistent image across target groups, and supports clearer positioning toward customers, partners, investors, and the capital market.
The renaming is part of a strategic process to standardize brand identity and does not affect the company's strategic direction, business model, or operational activities. The stock market listing and existing shareholder rights remain unchanged. The company will continue to operate under its current leadership and business operations.
Novogenia AG, headquartered in Munich, Germany, is a European healthcare company active in human genetics and personalized products. Its genetic analyses are used in disease diagnosis, treatment, and prevention, as well as in producing tailored nutritional supplements and cosmetics. The company also partners with physicians, therapists, pharmacists, nutritionists, and fitness trainers to optimize patient care based on genetic predispositions. Additionally, Novogenia holds investments in innovative biotech, healthcare, and life sciences companies.
For more information, visit https://novogenia.com/novogenia-ag. View the original release on www.newmediawire.com.
